Vistagen Therapeutics (VTGN) Market Capitalization (2012 - 2026)

Vistagen Therapeutics has disclosed Market Capitalization across 15 years of filings, most recently posting $10.2 million for Q2 2026.

• In Q2 2026, Market Capitalization fell 83.37% year-over-year to $10.2 million; the TTM figure through Jun 2026 stood at $10.2 million (down 83.37% YoY), while the FY2026 annual figure was $23.4 million, down 67.91% from the prior year.
• Market Capitalization came in at $10.2 million for Q2 2026 at Vistagen Therapeutics, down from $23.4 million in the prior quarter.
• In the past five years, Market Capitalization ranged from a high of $256.3 million in Q1 2022 to a low of $10.2 million in Q2 2026.
• Average Market Capitalization over 5 years is $79.1 million, with a median of $67.1 million recorded in 2025.
• Year-over-year, Market Capitalization sank 95.34% in 2022 and soared 582.51% in 2024.
• Over 5 years, Market Capitalization stood at $20.7 million in 2022, then soared by 570.87% to $138.9 million in 2023, then sank by 38.71% to $85.1 million in 2024, then tumbled by 69.29% to $26.1 million in 2025, then tumbled by 60.97% to $10.2 million in 2026.
• Per Business Quant data, the three most recent Market Capitalization figures were $10.2 million in Q2 2026, $23.4 million in Q1 2026, and $26.1 million in Q4 2025.